SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

DBI-2

Cat. No.:	HY-162516
CAS No.:	2939087-00-8
Molecular Formula:	$C_{24}H_{29}BrN_2O_3$
Molecular Weight:	473.4
Target:	AMPK; Mitochondrial Metabolism
Pathway:	Epigenetics; PI3K/Akt/mTOR; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

DBI-2 is an AMPK activator targeting mitochondrial complex I. DBI-2 disrupts the OXPHOS process, and reduces ATP generation in mitochondria. DBI-2 inhibits the proliferation of colorectal cancer (CRC) cells[1].

In Vitro

The IC_{50} of DBI-2 to inhibit the proliferation of LS174T cells and HCT116 cells was 1.14 μM and 0.53 μM, respectively[1].
DBI-2 (3 μM; 24 h) induces growth suppression by activating AMPK and inhibiting the mTOR and Wnt pathways[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	LS174T CRC cells
Concentration:	3 μM
Incubation Time:	24 h
Result:	Increased p-AMPK and p-ACC, and decreased p-P70S6K and p-S6, and reduced the expression of Axin2 and c-Myc.

In Vivo

DBI-2 (40 mg/kg; ip; for 12 days) inhibits tumor growth in olorectal cancer (CRC) xenograft mouse models[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	$RAG1^{-/-}$ γc^{-} mice injected with S174T cells[1]
Dosage:	40 mg/kg
Administration:	Intraperitoneal administration; for 12 days
Result:	Suppressed of tumor growth.

REFERENCES

[1]. Lichao Guo, et al. Inhibition of Carbohydrate Metabolism Potentiated by the Therapeutic Effects of Oxidative Phosphorylation Inhibitors in Colon Cancer Cells. Cancers (Basel). 2024 Apr 2;16(7):1399.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA